Major depressive disorder (MDD) is a debilitating disease that is characterized by at least one discrete depressive episode lasting at least 2 weeks and involving clear-cut changes in mood, interests and pleasure, changes in cognition and vegetative symptoms. BOX 1 describes the current diagnostic criteria and speci fiers (which enable clinical subtyping) of MDD according to the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5), which was released in 2013 (REF. 1). The cluster of symptoms that characterize a major depressive episode and MDD overlap with depressive symptoms in schizophrenia and bipolar disorder; the application of exclusion criteria enables a diagnosis of MDD.
psychotherapy include the use of behavioural intervention technologies. With regard to pharma cological approaches, glutamatergic antidepressants, such as ketamine, are currently under scientific scrutiny after promising initial findings of efficacy.
In this Primer, we provide an overview of the current evidence of MDD, including its epidemiology, aetiology, pathophysiology, diagnosis and treatment. We also outline the key outstanding research questions in the field that should be addressed in the coming years.
Epidemiology

Prevalence and main correlates
A best estimate of the worldwide MDD prevalence comes from the World Mental Health (WMH) Survey, which assessed the DSM-IV criteria for MDD among almost 90,000 individuals in 18 countries from every continent 3 . The average 12-month prevalence of MDD is approximately 6%, which is in line with estimates from earlier large-scale international studies 3 . Lifetime MDD prevalence is typically threefold higher than the 12-month prevalence, indicating that MDD affects one in every six adults 3 . Although lifetime prevalence is an unreliable metric as it probably suffers from recall bias and underestimation 14, 15 , it indicates that about 20% of all people fulfil the criteria for MDD at some point in their lifetime.
The 12-month MDD prevalence in the WMH Survey ranged from 2.2% in Japan to 10.4% in Brazil (FIG. 1) . Although estimates varied substantially across countries for reasons that probably involve both substantive and methodological processes, the 12-month MDD prevalence was found to be similar in ten high-income (5.5%) and eight low-income and middle-income (5.9%) countries, showing that MDD is not just a 'modernworld' health condition. In addition, the median age of onset, severity, symptom profile and basic sociodemographic and environmental correlates (such as sex, education and life events) of MDD are mostly compar able between countries and cultures 16, 17 . The discrepancy between countries is evident in terms of the resources and treatments available. In high-income countries, approximately 50-60% of all people with severe MDD receive proper treatment 18, 19 , whereas in low-income countries <10% of patients do 18 . Women have a twofold increased risk of developing MDD than men after puberty 2 . This disparity reflects the more-frequent occurrence of episodes in women, rather than longer episode duration, differential treatment response or higher recurrence rates in women compared with men 20, 21 . In both sexes, the median reported age of onset of MDD is approximately 25 years and the peak risk period for MDD onset ranges from mid-to-late adolescence to early 40s 3 . These findings are in line with observations that, especially in high-income countries, the MDD prevalence generally modestly decreases with age after early adulthood 16 .
Other consistently reported environmental determinants of MDD in both men and women are the absence of a partner (for example, owing to divorce or widowhood) and the experience of recent negative life events, such as illness or loss of close relatives or friends, financial or social problems and unemployment 3, 22 . In addition, a range of social determinants (including childhood adversities, socioeconomic status and low social support) as well as low educational attainment 23 significantly increases the risk of MDD in men and women (BOX 2) . However, the cause-effect relationship between lower educational attainment and MDD is unclear and a large study with 25,000 individuals recently suggested that it might partly be due to shared genetics 24 . Individuals with a history of childhood trauma have a more than twofold increased risk of developing MDD 25 . Furthermore, patients with MDD and a history of childhood trauma show higher symptom severity, a poorer course and more treatment non-response than patients with MDD without childhood trauma 26 .
Disease course
The course of MDD is pleomorphic, with considerable variation in remission and chronicity; higher symptom severity, psychiatric comorbidity and a history of childhood trauma all predict a less favourable course 21, 26 . In population-based samples, the mean episode duration varies between 13 and 30 weeks and approximately 70-90% of patients with MDD recover within 1 year [27] [28] [29] . However, in outpatient care settings, the course is less favourable: only 25% remit within 6 months and >50% of patients still have MDD after 2 years 21, 30, 31 . After MDD remission, residual symptoms and functional impairment often remain 32 . In addition, the chance of MDD recurrence is high, as about 80% of patients in remittance experience at least one recurrence in their lifetime 33 . The course trajectory in adults seems to be slightly less favourable with increasing age than in younger patients 21 .
Disease burden
The Global Burden of Disease Consortium found that, in 2013, MDD was the second leading contributor to global disease burden, as expressed in disability -adjusted life years, in both developed and developing countries Moreover, the consequences of MDD extend to physical health. Large-scale longitudinal studies converge in their findings suggesting that MDD increases the risk of diabetes mellitus, heart disease, stroke, hypertension, obesity, cancer, cognitive impairment and Alzheimer disease 34 (FIG. 2) . Both in the general population and in populations with specific medical illnesses, MDD increases the mortality risk by 60-80% 35, 36 . Indeed, the contribution of MDD to all-cause mortality is 10%.
Mechanisms/pathophysiology
Despite advances in our understanding of the neurobiology of MDD, currently no established mechanism can explain all facets of the disease. Animal models of MDD are available and have enabled the discovery of many potentially implicated pathways (BOX 3) , although the applicability of these findings in humans is still nascent. Accordingly, we restrict our description to pathophysiological models of MDD that are supported by findings from clinical studies, giving preference to aspects that have been confirmed in meta-analyses and pathways that have been targeted in clinical trials ( ideally also with a meta-analysis level of evidence).
Genetics
We have known for more than a century that MDD clusters within families. First-degree relatives of patients with MDD show a threefold increased risk of MDD and heritability for this disorder has been quantified as approximately 35% 37 . Furthermore, genetic overlap between MDD and other psychiatric disorders, such as schizo phrenia and bipolar disorder, has been identified 38, 39 . However, the search for main genetic effects in MDD so far has not revealed consistent or replicated significant findings 40 , as indicated by a large-scale analysis of various GWAS that included 9,240 cases and 9,519 controls 41 . Similarly sized studies of other psychi atric conditions such as schizophrenia, which has higher heritability than MDD, have convincingly implicated at least some genetic loci; for schizophrenia, 108 independent genome-wide significant loci have been shown 42 . Risk of MDD is highly polygenic and involves many genes with small effects 43 , which coupled with the heterogeneity of MDD phenotypes requires very high numbers of patients to find signifi cant associations. A recent genome-wide association study in Chinese patients in which a more homo geneous phenotypic approach (recurrent MDD requiring outpatient care) was applied was able to confirm two genome-wide significant genetic loci 44 . Moreover, 15 genetic loci with genome-wide significance have been associated with risk of self-reported MDD in 75,607 patients and 231,747 controls of European descent 45 . Furthermore, some recent studies in >100,000 subjects have also indicated several genome-wide significant loci for neuro ticism, a phenotype that is strongly correlated to MDD 46, 47 . This finding holds promise for the ongoing search for consistent genetic variants that contribute to MDD risk in a collaborative genome-wide association study carried out by the Psychiatric Genomics Consortium (http://www.med.unc.edu/pgc).
Environmental factors
Early epidemiological studies focused on stressful events that are temporally related to MDD, usually in the year preceding onset; the main documented events (such as loss of employment, financial insecurity, chronic or life-threatening health problems, exposure to violence, separation and bereavement) 48 occur most often in adulthood. However, more-recent evidence has focused on exposure to events in childhood as antecedent of MDD later in life. These events include physical and sexual abuse, psychological neglect, exposure to domestic violence or early separation from parents as a result of death or separation, with clear evidence of a dose-response relationship between the number and severity of adverse life events and the risk, severity and chronicity of MDD 9 .
Box 1 | Definition of MDD according to DSM-5
• An individual will show five (or more) of the following symptoms, which should be present during the same 2-week period nearly every day and should represent a change from previous functioning The HPA axis is at the centre of the comprehensive neurobiological model that seeks to explain the long-lasting consequences of early trauma. Many animal studies have shown that early-life stress produces persistent increases in the activity of corticotropin-releasing hormone (CRH)-containing neural circuits 49 . This finding is supported by clinical studies showing that individuals who have been sexually or physically abused in childhood show, as adults, a markedly enhanced activity of the HPA axis when exposed to standardized psychosocial stressors or following endocrine tests that attempt to suppress HPA activity 50 . Indeed, glucocorticoid receptor function is reduced in these individuals (so-called glucocorticoid resistance), a finding that is supported by the fact that these individuals also show increased activation of the inflammatory system, which is under physiological inhibitory control by cortisol. Indeed, glucocorticoid resistance, HPA axis hyperactivity and increased inflammation are all evident in MDD (FIG. 3) .
Furthermore, in utero stress has also been shown to increase the risk of MDD later in life 51 . This novel but burgeoning area of research is providing further evidence of the neurodevelopmental origin of MDD and the long-lasting effects of environmental insults at the earliest stages of life 52 .
Gene-environment interactions
The lack of consistent and replicated findings in GWAS for MDD can at least partly be explained by the fact that relevant genetic variants confer an increased risk only in the presence of exposure to stressors and other adverse environmental circumstances -the so-called gene-environment (G×E) interaction (FIG. 4) . However, although several potential candidate genes, such as sodium-dependent serotonin transporter (SLC6A4), CRH receptor 1 (CRHR1) and the gene encoding peptidyl-prolyl cis-trans isomerase (FKBP5) have been identified, differences in the timings and the type of adverse environmental circumstances have hampered replication studies of single candidate genes.
Epigenetics. Interestingly, studies investigating the molecular mechanisms underlying G×E interactions have shown that they might involve epigenetic regulation 53 . For example, allele-specific, stress-dependent DNA demethylation in glucocorticoid-response elements of a polymorphism in FKBP5 has been observed 54 . This interaction leads to increased FKBP5 expression in response to stress, which in turn leads to glucocorticoid receptor resistance 55 . Furthermore, several studies have shown consistent epigenetic changes in the brains of animal models of MDD as well as in post-mortem brain samples of patients with MDD, especially suicide victims who were exposed to early-life adversities 56 . Initial hypothesisdriven studies examined genes involved in the stress response, but more-recent unbiased GWAS have implicated epigenetic changes in genes that are often unrelated to established candidates, therefore, implicating alternative pathophysiological mechanisms, such as cell adhesion and cell plasticity 54 . However, enthusiasm for epigenetic research in MDD is still limited by the small magnitude of the described epigenetic changes (often <10%), especially in comparison with other medical disorders, such as cancer 53 .
Neuroendocrinology
As mentioned, the HPA axis is among the most researched biological systems in MDD 57, 58 . For example, two meta-analyses 50, 59 concluded that cortisol levels in patients with MDD were increased, with a moderate effect size. Importantly, HPA alterations correlate with impaired cognitive function 60 in these patients, and are more common and more pronounced in severely depressed patients with melancholic and/or psychotic features 61 and in elderly patients who have MDD 62 . Furthermore, several studies have prospectively shown that increased levels of cortisol is a risk factor for subsequent MDD in at-risk populations 63, 64 . Finally, a study using data from a primary care database including >370,000 individuals indicated that treatment with synthetic glucocorticoids is associated with an increased risk for suicide (approximately sevenfold), MDD (approximately twofold) and other severe neuro psychiatric disorders, even when controlling for the underlying medical disorder 65 . Despite these findings, data from interventional studies are less clear. For example, antidepressants reduce the levels of cortisol in patients with MDD over the course of the treatment 66 . However, a meta-analysis has shown that, independent of improved psychopathology, approximately 50% of patients had similar cortisol levels before and after treatment. Increased levels of CRH in the cerebro spinal fluid (CSF) have been shown in patients with MDD 67 and, accordingly, several randomized controlled trials have examined CRH antagonists in the treatment of MDD. However, the Nature Reviews | Disease Primers overall results have not indicated a major role for CRH antagonists in the treatment of MDD 68 . Clinical trials using glucocorticoid-lowering compounds, such as metyrapone, have also yielded mixed results 69, 70 . Fludrocortisone, a mineralocorticoid receptor agonist, has been shown to accelerate the onset of action of standard antidepressants in one randomized controlled trial 71 and to improve cognitive function in patients with MDD in an experimental study 72 . In MDD with psychotic features, the glucocorticoid receptor antagonist mifepristone (also known as RU-486) was shown to ameliorate psychotic symptoms, although secondary analyses of failed trials indicated that very high doses might be required to reach therapeutic blood levels 58 . In summary, although there is unequivocal evidence of HPA alterations in MDD, this has not yet led to new therapeutic avenues. Deeper clinical and biological pheno typing of MDD will lead to the identification of MDD subtypes of patients who are more likely to respond to a given treatment within the HPA axis.
Inflammation
The immune system is an important component of the physiological stress-sensing pathways and closely interacts with the body's main integrative systems (the HPA axis, the autonomic nervous system and the central nervous system (CNS)) in mutually regulatory feedforward and feedback loops (FIG. 5) . A role for peripheral immune dysfunction and neuroimmunological mechanisms in MDD has been supported by a large body of evidence from animal studies
. These models have also provided intriguing insights into how peripheral cytokines can, directly and indirectly, affect brain circuits, behaviour and mood. Peripheral cytokines can be transported through the blood-brain barrier to act directly on CNS-resident cells, including astrocytes, microglia and neurons. In addition, inflammatory signals can be conveyed to the CNS through cellular mechanisms (CNS infiltration by peripheral immune cells) or signalling via the vagus nerve (the 'inflammatory reflex'). Animal models have shown that these routes converge in the CNS to alter molecular programmes (for example, receptor expression), neurogenesis and plasticity 73 . Clinical observations suggest that similar mechanisms of inflammation might also be relevant for the development of MDD in patients. For example, a population-based study has shown that both prior severe infections and autoimmune diseases increase the risk of subsequently developing MDD 74 . In addition, patients who receive cytokine treatments, such as IL-2 or interferon-γ (IFNγ), as part of their treatment for hepatitis virus infection or cancer often develop depressive symptoms 75 . Finally, patients with MDD show increased serum levels of cytokines, such as tumour necrosis factor (TNF) and IL-6, as confirmed by meta-analyses 76, 77 . Increased expression of genes involved in IL-6 signalling in peripheral blood cells has also been observed in a large-scale cohort study of patients with MDD compared with healthy controls 78 . There have also been a few large, prospective studies indicating that increased levels of IL-6 during childhood significantly increases the risk of developing MDD in adulthood 79 . Recent studies using PET imaging 80 as well as analyses of post-mortem brain tissue 81 have indicated neuroinflammation and microglial activation in the CNS of patients with MDD. Finally, a potential role for inflammation in MDD is also supported by clinical trials of NSAIDs, reviewed in a meta-analysis 82 .
Neuroplasticity
The peripheral changes in cortisol levels and inflammatory mechanisms might ultimately induce depressive symptoms by affecting brain function at a cellular level, primarily by disrupting neuroplasticity and, accordingly, neurogenesis -the process by which new neurons are generated in the adult brain from pluripotent stem cells. Along these lines, lower levels of the neurotrophin brain-derived neurotrophic factor (BDNF) have been measured in the sera of patients with MDD. BDNF and other regulators of neuroplasticity might affect behaviour through their control of neuro genesis. BDNF mRNA levels are also reduced in the leukocytes of patients with MDD, and pharmacological and nonpharmacological antidepressant therapies have been shown to normalize BDNF levels 83 . Although BDNF and other correlates of neuroplasticity have been implicated, the precise role of neuro genesis in MDD has been debated 84 . For example, reducing adult neurogenesis in rodents in the absence of stress does not induce depressive-like behaviour. However, reduced neurogenesis can precipitate depression-like symptoms in the context of stress. At a biological level, adult neurogenesis promotes resilience to stress by enhancing glucocorticoid-mediated negative feedback on the HPA axis 84 . Importantly, in rodents, effective adult neurogenesis occurs following anti depressant treatment that reduces stress responsiveness 84 . Thus, it is biologically plausible that neurogenesis contributes to the clinical effects of antidepressants in humans.
Monoamines
The monoamine neurotransmitters serotonin (also known as 5-hydroxytryptamine), noradrenaline and dopa mine were first implicated in MDD after it was discovered that substances such as the anti hypertensive
Box 2 | Social and environmental determinants of MDD
Several social and environmental factors are associated with the risk and the outcome of major depressive disorder (MDD) 208 . They can be categorized as demographic factors (for example, age, sex and ethnicity), socioeconomic status (for example, poverty, unemployment, income inequality and low education), neighbourhood factors (for example, inadequate housing, overcrowding, neighbourhood violence and safety), socioenvironmental events (for example, natural disasters, war, conflict, migration, discrimination, difficulties in work, low social support, trauma and negative life events) and lifestyle factors (for example, alcohol use, smoking behaviour, a high-fat or high-sugar diet and physical inactivity). A bidirectional association between these determinants and MDD is evident; certain social variables, such as low socioeconomic status or lack of social support, can contribute to the risk for MDD (a so-called social cause). By contrast, patients with MDD, especially those with a chronic course of the disease, often deteriorate in their social functioning, leading to work and family problems (experiencing 'social drift'), which may eventually lead to poverty 208, 222 . drug reserpine reduce their levels and that some patients taking these drugs developed MDD 85 . The role of monoamines in MDD was further supported by the discovery in the 1950s and, later, the mechanistic interro gation of the first antidepressant drugs -tricyclic antidepressants (TCAs) and monoamine oxid ase inhibitors (MAOIs). Both TCAs and MAOIs have robust effects on monoamine neurotransmission; TCAs block the reuptake of monoamines in the presynaptic neuron and MAOIs prevent their breakdown once reabsorbed, enhancing the effects of the neurotransmitters. These findings stimulated the development of a long series of monoamine-based compounds, which continue to dominate the field of modern psychopharmacology of MDD.
However, many studies that have measured noradrenaline and serotonin metabolites in the plasma, urine and CSF, as well as post-mortem studies of the brains of patients with MDD have yielded inconsistent results (reviewed in REF. 86 ). Furthermore, drugs that target monoamines affect these neurotransmitter systems within hours after administration. However, the antidepressant effects are often only evident after several weeks of treatment. Changes in brain gene expression that occur after continuous treatment with drugs that target monoamines might underlie their therapeutic effects 87 , rendering the monoamine hypothesis of MDD overly simplistic.
Structural brain alterations
It stands to reason that a combination of the molecular and cellular mechanisms of the pathobiology reviewed above might ultimately contribute to morphological changes in brain structure in MDD as detected by neuro imaging. Indeed, many cross-sectional studies using structural brain imaging have investigated regional brain volumes in patients with MDD. Although smaller volumes in many different brain areas have been reported in individual case-control studies, the best and most consistent evidence from structural MRI studies support that hippocampal volume is reduced in individ uals with MDD. For example, a meta-analysis of 143 studies 88 confirmed smaller volumes in patients with MDD than in healthy controls in the basal ganglia, thalamus, hippocampus and several frontal regions (FIG. 5) . A meta-analysis by the ENIGMA (enhancing neuroimaging genetics through meta-analysis) working group of MRI data from more than a dozen independent research samples detected significantly lower volumes in the hippo campus (but no other subcortical structures) 89 as well as cortical thinning in the orbitofrontal cortex, anterior and posterior cingulate, insula and temporal lobes in patients with MDD 90 . Furthermore, a large-scale trans-diagnostic voxelbased morphometry meta-analysis of 193 studies comprising 15,892 individuals also suggested that the hippocampus might be selectively affected in MDD compared with other psychiatric disorders, such as schizophrenia, bipolar disorder, addiction, obsessivecompulsive disorder and anxiety 91 . Although an earlier meta-analysis suggested that smaller hippo campal volumes might already be present in patients with firstepisode MDD 92 , this could not be confirmed in the most recent meta-analysis of MRI data by the ENIGMA working group 89 . Thus, whether smaller volumes of the hippocampus seen in MDD are an early manifestation or whether they develop later in the course of the disorder remains unclear.
Functional brain circuits
Several studies have suggested that stress-associated alterations in inflammatory and glucocorticoid signalling are associated with corresponding functional changes in multiple brain networks 93, 94 . Indeed, neuroimaging studies in MDD have identified abnormalities in either activation or connectivity within the affectivesalience circuit, the medial prefrontal-medial parietal default mode network and the frontoparietal cognitive control circuit.
Affective-salience circuit. The affective-salience circuit plays a central part in guiding motivated behaviour, whether related to emotional or cognitive stimuli, and includes projections between the dorsal cingulate, anterior insula, ventral striatum and amygdala, as well as downstream targets, such as hypothalamic and brain stem nuclei.
One of the most frequently reported neuro imaging findings in MDD is abnormally increased connectivity and heightened activation of the amygdala 95 . In addition, much like the amygdala, the dorsal anterior cingulate and anterior insula are hyperactive in MDD, which may reflect the increased salience of negative information and self-directed thoughts in MDD 95 . By contrast, decreased activity and connectivity of the ventral striatum and other reward-related regions have been observed in MDD, leading to decreased recruitment of saliency-processing areas, such as the dorsal cingulate and anterior insula 96, 97 . Evidence from meta-analyses 34 of longitudinal studies has revealed that the relative risk (RR) of various diseases is increased in those with major depressive disorder (MDD) compared with those who do not have MDD. The mechanisms that contribute to the diverse somatic consequences of MDD are complex and together might explain the unfavourable health outcomes in patients with MDD. They include unhealthy lifestyle, poorer care (or selfcare) adherence, adverse effects of medications and shared pathophysiology (for example, upregulation of immune-endocrine stress systems, which is present in MDD but also in obesity). These contributions are explained in more detail elsewhere 5, 34 .
Default mode network. The default mode network is characterized by greater activity during 'resting' states in which most mental activity is internal or self-directed. Difficulties in dynamic modulation of the default mode network in MDD has been proposed to underlie excessive self-focus and rumination 95, 98 . Indeed, the default mode is hyperconnected in MDD 99 , which correlates positively with measures of rumination 100 . By contrast, the dynamic coupling between frontoparietal activ ation (which increases with task-directed attention) and default mode deactivation is perturbed in MDD 101, 102 , which might contribute to cognitive deficits in patients with MDD.
The frontoparietal cognitive control circuit. The frontoparietal cognitive control network is engaged across many cognitive tasks 103 . A recent meta-analysis found evidence for frontoparietal hypoconnectivity in MDD, especially of the dorsolateral prefrontal cortex, implicating it in goal-directed attention deficits in MDD 104 . Moreover, decreased frontoparietal connectivity has been shown both at rest and in response to negative stimuli, but not in response to positive stimuli, suggesting that this network may contribute to inappropriate cognitive appraisals of negative events 105, 106 .
Diagnosis, screening and prevention
Differential diagnosis
According to DSM-5
, MDD is distinguished from normal sadness or bereavement; however, in patients who, for example, are mourning and who develop symptoms that are severe enough and that persist beyond the acute grieving period, an MDD diagnosis can be given. Although it is possible to diagnose MDD on the basis of a single depressive episode of ≥2 weeks, MDD is recurrent in the majority of cases 1 . The key differential diagnoses of MDD are with bipolar disorder, with persistent depressive disorder and with schizophrenia. The differential diagnosis of bipolar disorder rather than MDD rests entirely with the presence of a history of hypomania or mania, which is characterized by a clear period of elevated mood or irritability, and with at least three of the following symptoms: inflated self-esteem; reduced need for sleep; increased speech; flight of ideas; distractibility; increased activity in goal-directed tasks; and/or involvement in risky behaviour.
Persistent depressive disorder is a chronic dis order and describes patients who have had depressive symptoms for >2 years. Apart from depressed mood, only two of six symptoms (appetite disturbance, sleep disturbance, loss of energy, decreased self-esteem, poor concentration or hopelessness) are required for the diagnosis. Thus, it is possible to meet criteria for persistent depressive disorder without having MDD. If a patient meets criteria for MDD, then the patient would receive two diagnoses -MDD and persistent depressive disorder. Finally, for an MDD diagnosis, the depressive episode must not be better explained by schizophrenia, schizoaffective disorder or other psychotic disorders
.
Specifiers of MDD
Once a diagnosis of MDD is made, the condition can be further characterized using various modifiers or specifiers 1
. The first specifier, severity of episode, is rated from mild to moderate to severe. Severe symptoms have a substantial effect on function.
With anxious distress. The specifier 'with anxious distress' was introduced because patients with MDD with considerable co-occurring anxiety are more likely to report suicidal thoughts and be less responsive to traditional antidepressants than others. The specifier requires experience of at least two of the following: a sense of being 'keyed up' or tense; unusual restlessness; trouble concentrating secondary to worry; fear that awful things will happen; and worry about losing self-control. These symptoms need to be present most of the days that the patient experiences an episode of MDD.
With mixed features. The specifier 'with mixed features' reflects an idea that MDD lies on a continuum with bipolar disorder and that patients with either diagnosis can show features of the other during an index episode 1 . This hypothesis is based on the observation that some patients with MDD show rapid thinking and reduced need for sleep, which are characteristic of bipolar disorder. The criteria include experiencing at least three of the following symptoms during the depressive episode: elevated and expansive mood; heightened self-esteem or grandiosity; increased speech or pressure of speech; racing thoughts; increased energy or directed activity; excessive activity in behaviour with possibly negative consequences; and/or reduced need for sleep. A pressing clinical question is whether MDD with mixed features requires a different therapy than MDD without mixed features. Finding the appropriate model systems for a given human disease is always challenging, particularly for psychiatric disorders 223 . Developing animal models is further complicated by the lack of consistently identified genetic risk factors of depression in humans. Moreover, many of the symptoms typically experienced by patients with major depressive disorder (MDD) are highly subjective (such as depressed mood) and only few can be objectively observed and assessed in animals. Despite these challenges, animal models have enabled the discovery of several target pathways that might contribute to the pathogenesis of MDD and have facilitated the study of the implicated molecular processes. These pathways include but are not limited to neuroendocrine 57 and immune 214 mechanisms, epigenetics 224 , molecular networks and the transcriptome 225 , the microbiota and the gut-brain axis 226 , synaptic dysfunction and plasticity 227 and neurogenesis 228 . Indeed, this fascinating and highly active area of investigation has the potential to uncover novel targets for therapy and ultimately to bring about better treatments for patients. However, the clinical relevance of many of these mechanisms for MDD remains uncertain; no newly developed, hypothesis-driven therapeutic approaches for depression have yet made it to the clinic.
lack of pleasure and loss of reactivity to positive stimuli, distinct quality of depressed mood (such as despair), depression worse in the morning, waking early in the morning, psychomotor disturbance, weight loss and excessive guilty thoughts.
With atypical features. The specifier 'with atypical features' refers to a set of symptoms that are common in MDD. The criterion of mood reactivity in atypical depression requires that mood brightens in response to actual or potential positive events, which is in contrast Nature Reviews | Disease Primers Clinical studies in major depressive disorder (MDD) and relevant animal models have identified pathophysiological features in the central nervous system, as well as the major stress response systems, such as the hypothalamic-pituitary-adrenal (HPA) axis, the autonomic nervous system and the immune system. In the central nervous system, altered neurotransmission and reduced plasticity are evident. These could underlie functional changes in relevant brain circuits (for example, cognitive control and affective-salience networks), smaller regional brain volumes (for example, in the hippocampus) and neuroinflammation, as confirmed in neuroimaging studies. Beyond the central nervous system, chronic hyperactivity impairs feedback regulation of the HPA axis, which is one of the most consistently reported biological features of MDD. Within the immune system, substantial evidence supports increased levels of circulating cytokines and low-grade chronic activation of innate immune cells, including monocytes. However, other aspects of immunity seem to be impaired as exemplified by reduced natural killer (NK) cell cytotoxicity and T cell proliferative capacity. Once it becomes chronic, both HPA axis hyperactivity and inflammation might converge with alterations in the autonomic nervous system to contribute to central nervous system pathobiology as well as cardiovascular and metabolic disease, which often co-occur with MDD. The sequence of events leading to changes in these interconnected systems and their exact relationship is not known. However, mechanistic studies in animals have shown that alterations in stress response systems can directly and indirectly affect the central nervous system
Signs and symptoms
. Conversely, chronic stress and associated changes in behaviour can reproduce many of the stress system alterations, including HPA feedback impairment and inflammation, which suggests a bidirectional link between central and peripheral biological features of MDD. ACTH, adrenocorticotropin; CRH, corticotropin-releasing hormone; TNF, tumour necrosis factor.
to the 'with melancholic features' specifier. Other criteria for 'with atypical features' include at least two out of the following: significant increase in weight or appetite; increased sleep; a sense of leaden paralysis; and interpersonal sensitivity.
With psychotic features. Previously, the 'with psychotic features' specifier in DSM-IV was included as part of the severity continuum from mild to severe with psychotic features. In DSM-5, psychotic features were separated from the severity specifier because the two were not always highly correlated (that is, mild MDD can also present with psychotic features) 107 . Psychotic features in MDD are mostly mood-congruent, that is, the content of delusions or hallucinations is consistent with the typical depressive themes of personal inadequacy, guilt, disease, death, nihilism or deserved punishment. However, mood-incongruent psychotic features that do not include these typical themes can also occur.
With catatonic features. The specifier 'with catatonic features' refers to marked psychomotor disturbance that may involve decreased motor activity, decreased engagement during interview or physical examination, or excessive and peculiar motor activity. These patients are often psychotic.
Research Domain Criteria
In addition to DSM-5, the US National Institute of Mental Health (NIMH) developed the Research Domain Criteria (RDoC) that are not meant to be a diagnostic system but a framework for organizing research. The RDoC approach consists of a matrix in which the rows represent specified functional constructs characterized by genes, molecules, cells, circuits, physiology, self-report and paradigms used to measure it 108 . Constructs are in turn grouped into five higher-level domains of functioning: negative valence systems (encompassing fear, anxiety and loss); positive valence systems (encompassing reward seeking and consummatory behaviour); cognitive systems; systems for social processes; and arousal and regulatory systems (responsible for generating activation of neural systems as appropriate for various actions and homeostatic control, for example, energy balance and sleep). The ultimate goal of RDoC is to develop a deeper understanding of the biological and psycho social basis of psychi atric disorders, which might help to improve current classification systems 109 .
Screening
Screening is controversial in the MDD field. Many experts argue that screening for depression is of obvious benefit because MDD is often overlooked in medical settings 110 . By contrast, others state that it is impractical to implement universal screening and argue that there is a lack of evidence to support screening 111 . A recent systematic review included 71 studies and assessed the benefits and harms of screening for depression in primary care 112 . The authors concluded that the overall evidence of health benefit of depression screening in primary care is weak. However, the existing data 112 indicate that screening programmes generally increase the likelihood of remission and treatment response in general adult populations, but only in the presence of subsequent treatment offers.
Prevention
Given the high prevalence of MDD, effective prevention strategies such as strengthening protective factors (for example, increasing social support or problem-solving skills) or diminishing prodromal disease stages (such as reducing depressive symptoms before they fulfil criteria for MDD) might have an enormous public health impact in reducing disease burden.
The effects of preventive psychological interventions on the incidence of MDD were systematically examined in a meta-analysis of 32 randomized controlled trials 113 . The meta-analysis included studies examining universal prevention (in a whole population group regardless of risk status), selective prevention (in individuals or subgroups at increased risk of developing depression) and indicated prevention (in individuals identified as having prodromal symptoms of depression). The results indicated a 21% decrease in the incidence of MDD in the prevention groups compared with control groups who did not receive preventive interventions 113 . The authors concluded that prevention of MDD seems feasible and may be an effective way to reduce the numbers of incident MDD cases.
Management
In the management of MDD, there are two main initial treatment options: psychotherapy and pharma cotherapy. Different guidelines concur that moderate-to-severe depressive episodes should be treated with medication or with a combination of medication and psychotherapy [114] [115] [116] [117] . By contrast, a mild depressive episode can be initially treated with psychotherapy alone. However, patient preferences and prior treatment history should always be taken into account. Furthermore, in a mild depressive episode it is also possible to pursue an initial strategy of 'watchful waiting' without treatment. The schematic depicts a model that is based on predisposing genetic vulnerabilities that interact with aversive and protective environmental factors in the development of major depressive disorder (MDD). At least some of the environmental effects are mediated through epigenetic mechanisms to produce the phenotype of MDD, which is characterized by alterations on a molecular level, on a brain network level and on a behavioural level.
However, this period should not exceed 2 weeks, after which time treatment should be started in case the mild depressive episode has not resolved 116 . FIGURE 6 depicts a stepped-care model, which aims to guide patients, carers and practitioners in their treatment decisions 115 .
Psychotherapy
Psychotherapy for MDD comes in many different forms, the most common of which are described in BOX 4. These different paradigms rely on different conceptual models and prescribe techniques that vary to some degree in their focus and methods. A large number of ran domized controlled trials and meta-analyses consistently show that psychotherapy is effective in treating MDD; no consistent or clinically meaningful differences are evident between different types of psychotherapy [118] [119] [120] . This conclusion 121 has led to two broad hypotheses to explain the efficacy of psychotherapies.
The first hypothesis -the nonspecific or common factors explanation -argues that the primary agents for change in psychotherapy are mainly those that are common to all psychotherapies, such as the therapeutic alliance (a positive, warm, caring and genuine stance) 122 and therapist factors 123 . The common factors approach would suggest that focusing on training and quality assurance for these common factors will optimize treatment outcomes.
By contrast, proponents of the specific-factors explan ation argue that treatment-specific strategies produce change via different pathways, such as cognitive restructuring, behavioural activation or improved interpersonal functioning 124 . Accordingly, head-to-head comparisons of different psychotherapeutic treatment models, which are grossly underpowered to detect treatment differences 125 , hide patient variables such as the severity of depression, social dysfunction and cognitive dysfunction, which have been shown to differentially predict outcomes for different treatments 126, 127 . To the degree that the specific factors hypothesis is true, treatment outcomes might be optimized by tailoring specific interventions to patient characteristics.
Psychotherapy produces effects that are mostly equivalent to pharmacotherapy, although effect sizes from pharmacological and psychotherapeutic trials cannot be readily compared because of methodological issues (for example, blinding) 128 . A recent individual patient data meta-analysis, combining data across 16 trials that compared individual psychotherapy to antidepressant medication, showed no meaningful differences in outcomes on self-reported depression or rates of response or remission 129 . The beneficial effects of cognitive therapy have been shown to persist for at least 1 year post-treatment, which is similar to keeping people on antidepressant medications, and with lower relapse rates than in patients who withdraw from medications 130 . Although psychotherapy is clearly effective, many people have barriers to access, including time constraints, lack of available services and cost 131, 132 . Providing psychotherapy over the telephone has been repeatedly shown to be an effective medium for delivering psycho therapy 133 , producing outcomes that are equivalent to face-to-face therapy and reducing dropout 134 . Furthermore, group therapy is often recommended as a less costly way of providing treatment, particularly for Nature Reviews | Disease Primers Brain areas with smaller volumes in MDD include the basal ganglia, thalamus, hippocampus and frontal regions, typically with volume differences between 3.5% and 15.5% (left graph) and moderate effect sizes (right graph; error bars indicate 95% confidence intervals). Smaller volumes in the basal ganglia and the hippocampus have also been confirmed when comparing patients with MDD to those with bipolar disorder, suggesting some specificity of these areas for the depressive symptoms that are characteristic of unipolar MDD. Finally, in an independent meta-analysis of structural MRI data using voxel-based morphometry, only smaller volumes in the hippocampus were specific to patients with MDD when compared with other psychiatric disorders. Volume group differences, effect sizes and confidence intervals of MDD compared with healthy controls are based on data from Kempton et al.
88
, as are the comparisons of MDD and patients with bipolar disorder. Comparisons of MDD with bipolar disorder, schizophrenia, anxiety disorders, obsessive-compulsive disorder or substance use disorder are based on data from Goodkind et al. 91 .
patients with mild-to-moderate symptoms 135 . Trials comparing individual to group psychotherapy have shown individual treatment to be moderately superior to group post-treatment, although these differences disappear at 3-month follow-up 136 .
Technology-supported care. Behavioural intervention technologies, which use computers, tablets and phones to teach self-management skills 137 , are effective at reducing symptoms of MDD, when applied correctly. Although standalone technology-based interventions have not shown consistent benefits, primarily because people with MDD do not adhere to them, internet-based tools, combined with low-intensity coaching via phone or messaging, are highly effective at reducing symptoms of depression 138, 139 . Evidence for the efficacy and costeffectiveness of these coached intervention technologies has led to their being integrated into national mental health services in several countries, including England 140 and Australia
141
. However, well-designed head-to-head comparisons of technology-supported care and more-traditional forms of psychotherapy or pharmacotherapy have yet to be carried out. Accordingly, whether patients can be identified who might respond better to technologybased treatments than to traditional treatments is unclear. Indeed, as attitudes and expectations about the role of technology in daily life change, the patients who are likely to respond to such treatments will probably change. The rapid rate at which technology advances means that technology-based interventions will continue to grow and evolve rapidly 142 .
An emerging area of technology is digital phenotyping, which harnesses the growing availability of data generated continuously in the course of daily lives to create behavioural markers related to depression. For example, mobile phones, with a growing complement of sensors, have become personal sensing systems. As people tend to keep their phones with them, phone sensors can continuously estimate the severity of depression in real time 143 . This technology opens the possibility of intervention tools that can detect and react to sensed states and behaviours, enabling just-in-time prompting and reinforcement of treatment-congruent behaviours 144 , as well as tools that can passively monitor the risk of depression. Harnessing personal sensing platforms has the potential to shift our treatment tools from episodic to continuous, from reactive to proactive and from provider-centred to patient-centred 145 .
Pharmacotherapy
Three decades after monoamine neurotransmitters were implicated in MDD, it became clear that the narrow focus on increasing monoamine levels in the synaptic cleft (by blocking reuptake or degradation of monoamines) was overly simplistic. Now, anti depressants are known to induce neural plasticity and the modulation of monoamines is only the first of their therapeutic effects 146 .
Mechanisms of action.
Monoamine-based antidepressant drugs are thought to initiate an adaptive neuronal response to the biochemical perturbations in the synapse. Downstream changes in intracellular signalling pathways as well as changes in gene expression and neural and synaptic plasticity (including hippocampal neurogenesis) might have crucial roles in these adaptive changes 147, 148 , although the exact mechanism by which antidepressants exert their effects remains incompletely understood.
Given the now understood complexity of the activity of these drugs, the usefulness of the standard classification of antidepressant drugs, typically based on the speci fic effects on individual monoamine neurotransmitters, has been challenged 149 . However, such classification, often reflecting the affinity of drugs for presynaptic and postsynaptic monoamine receptors and/or monoamine transporters, has been useful in understanding some of their adverse effects. An international initiative from five scientific organizations with a focus and expertise in neuropsycho pharmacology recently developed the Neuroscience-based Nomenclature 149 of psychotropic drugs that, instead of grouping drugs according to indications (such as antidepressants or anti psychotics), organizes medications on the basis of their known pharmaco logical actions (such as selective serotonin reuptake inhibitors (SSRIs) and serotonin-noradrenaline reuptake inhibitors (SNRIs)).
In summary, monoaminergic neurotransmission is extremely complex and includes several neurotransmitters, presynaptic and postsynaptic receptors, transporters and enzymes that determine the availability and the effects of the specific monoaminergic transmitter (FIG. 7) .
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Severe and complex depression*; risk to life; severe self-neglect Medication, high-intensity psychological interventions, electroconvulsive therapy, crisis service, combined treatments, multi-professional and in-patient care
Step 4 Persistent subthreshold depressive symptoms or mild to moderate depression with inadequate response to initial interventions; moderate and severe depression Medication, high-intensity psychological interventions, combined treatments, collaborative care ‡ and referral for further assessment and interventions
Step 3
Persistent subthreshold depressive symptoms; mild to moderate depression Low-intensity psychosocial interventions, psychological interventions, medication and referral for further assessment and interventions
Step 2
All known and suspected presentations of depression Assessment, support, psychoeducation, active monitoring and referral for further assessment and interventions
Step 1 Figure 6 | Stepped-care model in the management of MDD. The stepped-care model proposes that the least intrusive, most effective intervention is provided first. If the initial intervention shows no benefit or if the individual declines an intervention, an appropriate intervention from the next step should be offered. *Complex depression includes depression that shows an inadequate response to multiple treatments, is complicated by psychotic symptoms and/or is associated with considerable psychiatric comorbidity or psychosocial factors. ‡ Only for depression in which the person also has a chronic physical health problem and associated functional impairment. Tolerability and efficacy. The success of the SSRIs and SNRIs in displacing TCA drugs as first-choice agents was not based on established differences in efficacy, but rather on a generally more favourable adverse-effect profile, such as lack of anticholinergic and cardiac effects and a high therapeutic index (the ratio of lethal dose to therapeutic dose), combined with ease of administration. However, all of the monoamine-based anti depressant drugs, regardless of their pharmacological class, have fundamentally comparable modest efficacy, with response rates around 50%, and show a character istic delayed (typically more than several weeks) response to treatment 12, 150 . However, the SSRIs and SNRIs are also not devoid of considerable tolerability issues: common acute treatment adverse effects are nausea, insomnia, headaches, dizziness, gastrointestinal symptoms and sexual dysfunction, whereas common long-term adverse effects include weight gain, sexual dysfunction and sleep disturbances 151 . In the past two decades, there have been efforts to develop antidepressant drugs that are not monoaminebased, that are devoid of some of the untoward effects of these drugs and that are able to induce clinical changes in a much more rapid manner. Compounds that are under development include neurokinin 1 antagonists 152 , glutamatergic system modulators 153 , anti-inflammatory agents 154 , opioid tone modulators and opioid-κ antagonists 155 , hippocampal neurogenesis-stimulating treatments 156 and antiglucocorticoid therapies 157 . The degree of advancement in the development process varies across these different mechanisms, although all of these types of compounds have shown some degree of promise in the treatment of MDD.
Combined pharmacotherapy and psychotherapy
Several studies have shown that initiating treatment with both psychotherapy and pharmacotherapy produces significantly better outcomes than either treatment alone 158, 159 . Similarly, augmenting psychotherapy or antidepressant medications with the treatment not received when the monotherapy has not achieved satisfactory results is also effective at increasing the response rate 160 .
Treatment-resistant depression
The term treatment-resistant depression (TRD) is typi cally used to describe a form of MDD that has not responded adequately to at least one antidepressant 161 , although varying definitions of treatment resistance exist 162 . TRD is frequently observed in clinical practice, with up to 50-60% of patients not obtaining adequate response following a first antidepressant drug treatment 161 . A careful diagnostic re-assessment is considered crucial to the proper management of patients with TRD. More specifically, it is important to evaluate the potential role of several contributing factors, such as medical and psychiatric comorbidity. The degree of resistance to treatment can vary greatly among patients with TRD and some staging methods to classify TRD on the basis of different levels of treatment resistance have been shown to be of use clinically 163 . A meta-analysis showed several variables are associated with treatment resistance, including old age, marital status, long duration of current depressive episode, moderate-to-high suicidal risk, anxious comorbidity, high number of hospitalizations and comorbid personality disorders 164 . The most established strategies for treating TRD include psychopharmacological approaches, psychotherapy and electroconvulsive therapy (ECT).
Psychopharmacological strategies. Psychopharmacological approaches for TRD involve high-dose drug therapy or combination therapy. For example, the term high-dose treatment refers to a psychopharmacological strategy involving the considerable increase (doubling or tripling) of the dose of the antidepressant in the face of non-response, a strategy that has been shown to lead to significant improvements particularly in the event of partial response. This strategy has recently been confirmed in two meta-analyses looking at SSRI use 165, 166 . In addition, the strategy of switching involves changing the primary antidepressant drug to another of the same class or of a different class. In the STAR*D study,
Box 4 | Psychotherapy for MDD
Cognitive-behavioural therapy
Cognitive-behavioural therapy teaches the patient with major depressive disorder (MDD) to identify negative, distorted thinking patterns that contribute to depression and provides skills to test and challenge these negative thoughts, replacing them with more accurate positive ones.
Behavioural activation therapy
Behavioural activation therapy focuses on increasing the patient's positive activities that provide a sense of pleasure or mastery. This treatment also frequently focuses on identifying and confronting avoidance processes.
Psychodynamic therapy
Psychodynamic therapy helps the patient to explore and gain insight into how emotions, thoughts and earlier life experiences have created patterns that contribute to current problems. Recognizing these patterns can help a person to cope and to change those patterns.
Problem-solving therapy
Problem-solving therapy teaches patients a structured set of skills to generate creative methods to address problems, to identify and to overcome potential barriers to goals and to make effective decisions.
Interpersonal therapy
Interpersonal therapy focuses on helping people to identify and to resolve problems in relationships and social roles, including interpersonal conflicts, role transitions and diminished or impoverished relationships.
Mindfulness-based therapy
Mindfulness has its origins in contemplative practices, primarily Buddhism, and involves regular meditative practice in which one pays attention to thoughts, feelings and experiences in a non-judgemental manner, learning to accept things as they are without trying to change them.
this strategy led to remission in one in four patients who were citalopram (an SSRI) non-responders (both within the same class or within a different class), but its success in patients who have not responded to two antidepressant trials is extremely modest, with only one in ten patients achieving remission 12 .
Another approach in TRD is augmentation, in which ongoing antidepressant drug treatment is combined with non-antidepressant drugs. Initially well-studied augmentation strategies, such as lithium or l-triiodothyronine (T3) 167 , have become somewhat less common in practice, whereas augmentation with atypical anti psychotic drugs, such as quetiapine or aripiprazole, is increasingly being used 168 . Finally, combination treatment generally refers to the prescribing of more than one antidepressant simultaneously. The array and number of combinatory possibilities have dramatically increased with the introduction of newer antidepressant agents. The two best-studied combination strategies, studied in STAR*D, are SSRIs or SNRIs combined with either bupropion (a noradrenaline-dopamine reuptake inhibitor) or mirtazapine (an α2-adrenergic receptor antagonist) 12 .
Psychotherapy. In TRD, the most commonly used form of psychotherapy studied is cognitive-behavioural therapy
. A systematic review of the pertinent literature concluded that the current evidence examining the effect of psychotherapy as augmentation or substitute therapy in TRD is sparse and shows mixed results 169 . However, the use of cognitive-behavioural therapy in citalo pram non-responders in the STAR*D study was associated with comparable efficacy to pharma cotherapy 13 . Furthermore, a recent large-scale randomized controlled study showed both efficacy and long-term effectiveness of cognitive-behavioural therapy as adjunct to pharmacotherapy in TRD 170, 171 . Finally, compared with treatment as usual, a meta-analysis showed efficacy for the cognitive-behavioural analysis system of psychotherapy, which is a specific psychotherapy for chronic depression including TRD 172 .
ECT. In ECT, a seizure is elicited during short anaesthesia after the patient has provided informed consent. ECT is considered to be the most widely used and effective non-pharmacological biological treatment for TRD 173 . It is commonly used when a rapid anti depressant response is required, such as in very severely depressed and/or highly suicidal patients. The main tolerability issues of ECT are its adverse effects on cognition, especially anterograde and retrograde amnesia. Right unilateral ECT seems to be as effective as bilateral treatment, albeit bilateral treatment might lead to faster clinical response 173 . Another approach is to use ultra-brief pulse-width (UBP) stimulation to minimize cognitive adverse effects. However, a systematic review showed that UBP ECT might have lower efficacy and a slower speed of remission 174 .
Emerging treatments. Newer treatments for TRD include numerous approaches, such as repetitive trans cranial magnetic stimulation (rTMS), deep TMS (dTMS), magnetic seizure therapy (MST), trans cranial direct current stimulation (tDCS), low-field magnetic stimulation (LFMS), vagus nerve stimulation (VNS), deep brain stimulation (DBS), parenteral or intranasal ketamine and esketamine, as well as other pharmacological approaches.
Standard rTMS uses an eight-shaped coil to modulate neuronal activity to a maximum depth of 1.5-2.5 cm from the scalp. A recent review of 18 TRD studies of rTMS concluded that, for patients with MDD with at least two antidepressant treatment failures, rTMS is a reasonable, effective consideration 175 . However, a meta-analysis has shown that rTMS is inferior to ECT with regard to efficacy in TRD 176 . In contrast to standard rTMS, dTMS modulates neuro nal activity in deeper regions of the brain. One review concluded that dTMS in patients with TRD is effective both as a monotherapy and as an add-on treatment to pharmacotherapy 177 . MST combines elements of rTMS and ECT. In MST, an rTMS device is used to induce a seizure, but the procedure is otherwise carried out as ECT using a general anaesthetic and a muscle relaxant. A review of eight MST studies reported remission rates of 30-40% and no significant cognitive adverse effects 178 . tDCS typically applies a weak direct current via scalp electrodes overlying targeted cortical areas 179 . A recent review concluded that the data do not support the use of tDCS in TRD 180 . LFMS refers to a form of brain stimulation delivered in a magnetic field waveform inducing a low, pulsed electric field in the brain. Two sham-controlled pilot studies of LFMS have shown a rapid antidepressant effect in patients with a mood disorder, including patients with TRD 181 . VNS involves the surgical implantation of a pacemaker-like pulse generator in the chest, connected to a stimulating electrode attached to the vagus nerve in the neck. VNS results in the activation of various subcortical brain structures and the stimulation of hippocampal neurogenesis 182 . Despite the fact that the only controlled trial in TRD of VNS using a sham control did not achieve the pre-specified significance, and reported modest response rates in the acute phase, long-term, extension phases of VNS treatment have been associated with an increased therapeutic effect over time, with a sustained response rate of 40% and with a remission rate of 29% after a 9-month follow-up 182 . DBS involves the implantation of a pulse generator connected to two stimulating electrode wires, surgically placed in specific brain regions. DBS is typically reserved for patients with the most severe forms of TRD and requires further evaluation of administration methods and its role in MDD therapy 183 . A novel pharmacological approach to the treatment of TRD involves parenteral or intranasal administration of the glutamatergic drugs ketamine or esketamine, which are antagonists of N-methyl-d-aspartate (NMDA). A review of 21 studies showed that single ketamine intravenous infusions elicit a significant antidepressant effect from 4 hours to 7 days in patients with TRD 184 . Similar results were reported in a trial of a single intravenous infusion of esketamine 185 . Other drugs with NMDA receptor antagonistic properties have been associated with more-modest antidepressant effects than with ketamine; however, they have shown other potentially favourable characteristics, such as decreased dissociative or psychotomimetic effects. Other emerging pharma cological augmentation strategies use compounds such as S-adenosyl-methionine 186 , l-methylfolate 187 , omega-3 fatty acids 188 , intravenous scopolamine 189 and the opioid modulator ALKS 5461 (REF. 190 ), but their efficacy is not well established yet.
Quality of life
Much of the burden of disease associated with MDD is related to its dramatic effect of on one's ability to work and the strain on family life. In a large survey carried out in the United States, MDD was associated with 27.2 workdays lost per affected worker per year 191 . Another aspect affected in MDD is cognition. Finally, MDD is a major risk factor for suicidal ideation and of suicide attempts, which can significantly reduce the quality of life of patients and their families.
Cognitive impairment
Considerable literature has described objectively measured cognitive deficits in patients with MDD. These deficits affect a wide range of cognitive domains including both 'hot' (emotion-laden) and 'cold' (nonemotional) cognition. One meta-analysis identified executive function, memory and attention as the predominantly affected domains 192 . An attentional bias towards negative information has also been confirmed by meta-analysis 193 . Impairments in psychomotor speed, attention, visual learning and memory, as well as executive function can be detected with small-to-medium effect sizes during a first episode of MDD 194 . Although the cognitive deficits are modest after remission (that is, in euthymic patients with MDD), slight impairments in executive control 192, 195 and memory 192 can remain, suggesting that cognitive deficits are not simply an epiphenomenon of decreased motivation during episodes of low mood. Cognitive impairment in MDD partly depends on the patient subgroup studied. MDD severity, for example, has been shown to be a strong predictor of cognitive dysfunction 196 . In addition, patients with psychotic depression have been shown to do significantly worse than patients with non-psychotic MDD on tests of verbal learning, visual learning and processing speed 197 . Neurocognitive impairment is a relevant factor in the quality of life of patients, as it is negatively associated with psychosocial functioning in MDD 198 . Overall, antidepressant pharmacotherapy seems to improve cognitive function 199 .
Suicide risk
The most immediate clinical concern with MDD is its strong relation to suicidal intent and completed suicide 200 . Patients with MDD have a 1.8-fold increased overall mortality and patients with MDD lose an estimated 10.6 life years in men and 7.2 years in women 7 . This is due, in part, to the increased risk of suicide in this population. In one analysis, the risk of suicide in MDD was almost 20-fold higher than in the general population 7 . The effectiveness of behavioural and psychosocial interventions to prevent suicide and suicide attempts has been supported by a recent meta-analysis, particularly for interventions that directly address suicidal thoughts 201 . Strategies to reduce suicides at 'suicide hotspots' (that is, public areas often used for suicides) by aiming to restrict access and to encourage help seeking might be effective, at least according to a recent meta-analysis 202 .
Notably, meta-analyses of randomized controlled trials have not detected a beneficial effect of antidepressants to reduce suicide risk in MDD 203, 204 . Importantly, the association between antidepressants use and suicidality seems to be strongly age dependent 205, 206 . Metaanalyses revealed that suicidal ideation or behaviour associated with antidepressants was nonsignificantly increased in patients <25 years of age, nonsignificantly decreased in patients 25-64 years of age and highly signifi cantly decreased in patients >64 years of age. In any event, clinicians should pay special attention to suicidal ideation and suicidality in patients with MDD in general and during antidepressant pharmacotherapy 207 .
Outlook
Given that MDD is prevalent worldwide, one of the highest priorities in the field should be to implement effective treatment in low-income countries in which <10% of patients with MDD receive adequate treatment 208, 209 . The currently ongoing Mental Health Gap Action Programme (mhGAP) 210 of the WHO is aiming to scale-up services for mental disorders in countries with low and lower middle incomes.
In terms of the aetiology and pathophysiology of MDD, many questions remain unresolved. For example, how exactly is the immune system dysregulated in MDD? Are immunological alterations present in MDD in general or only in specific subtypes of the disease? Furthermore, there is a lack of replicated findings in both GWAS and G×E studies 37 . Thus, a crucial question remains how exactly environmental influences interact with the genome leading to MDD. In addition, how stable are epigenetic alterations of genomic read-out and are they reversible with successful therapy? An epidemiological phenomenon consists in the repeatedly described sex differences in prevalence rates of MDD 2 and it will be important to examine the mechanisms that are responsible for the increased MDD prevalence in women. Finally, given the fact that MDD is a strong risk factor for developing metabolic and cardiovascular diseases, and for a worse course and outcome in these diseases 5 , it will be important to learn more about the mechanisms of association between MDD and other medical diseases, such as diabetes mellitus or coronary heart disease. Future research should also examine whether treatment of comorbid MDD reduces morbidity and mortality in medical patients.
A pivotal task in the future of MDD research will be to break down the heterogeneous clinical picture of MDD as a broad DSM-5 category into more narrowly defined disease entities with specific biologies. The initial goal of DSM-5 was to define psychiatric diagnoses by genetics, neuroimaging and other biological measures. However, our knowledge has not yet sufficiently progressed to reliably base psychiatric diagnoses on biological measures. Nevertheless, the DSM still provides clinicians and researchers with the opportunity to define subtypes of MDD by grouping patients according to distinct clinical characteristics (for example, melancholic versus atypical depression). Importantly, these subtypes have already been associated with different neurobiological signatures 34 . Furthermore, the concepts of 'vascular depression' (REF. 211 ), 'metabolic depression' (REFS 212, 213) or 'inflammatory depression' (REF. 214 ) that all imply a specific aetiology and potentially specific treatments warrant further validation.
Once valid MDD subtypes have been identified, specific treatments associated with better outcomes will hopefully follow. Several studies have predicted response to specific psychological or pharmacological treatment by clinical criteria such as history of childhood trauma 215 , neuroimaging markers such as insula hypometabolism 216 or inflammatory markers such as C-reactive protein 217, 218 . However, clinical subtypes (melan cholic, atypical and anxious) could not predict treatment response in the iSPOT-D trial 219 . Ideally, so-called precision psychiatry will enable categorization of MDD subtypes as in the field of oncology, which has started to define different forms of cancer in the same organ into separate disease entities that require different treatment 220 . It remains to be seen whether the dimensional approach of the RDoC using concepts from genetics as well as from cognitive, affective and social neuroscience will achieve this goal. It has been argued that the RDoC approach disregards the distinction between 'sick' and 'well' and that the RDoC might introduce a gap between clinicians using DSM-5 and researchers using RDoC 221 .
Better treatment for patients is the ultimate goal of all biomedical research and obviously this is true for MDD research as well. In terms of new psychotherapeutic approaches, the technological revolution with its fast evolving developments will enable technology-supported diagnostic and treatment options. This might include intervention tools that can detect and react to sensed states and behaviours, allowing just-in-time prompting and reinforcement of treatment congruent behaviours 144 , as well as tools that can passively monitor risk of MDD.
Within pharmacological research, antidepressants that affect the glutamatergic system, such as ketamine, are currently under intense scientific scrutiny. A novel approach might be to use substances that stimulate neurogenesis in humans. The first (to our knowledge) phase Ib clinical study of the neurogenesis stimulator NSI-189 phosphate has been reported, showing efficacy compared with placebo in two out of four MDD outcome measures 156 . However, future studies are necessary to determine short-term and long-term safety and efficacy of substances that stimulate neurogenesis in patients.
MDD has considerable effects on the human condition and its aetiology and pathophysiology remain a complex puzzle. Consistent with Winston Churchill's famous quote "Success is not final, failure is not fatal: it is the courage to continue that counts", it will be worth every effort to relieve the enormous burden of MDD.
